Altimmune (ALT) just closed a big $225M oversubscribed funding round in late April, giving the company a solid runway to push its lead drug pemvidutide into Phase 3 for MASH. With Q1 earnings coming up on May 13, the stock looks primed for a bounce back toward the $5–6 zone as the financing overhang clears and investors focus on the upcoming catalysts. Smart money (RA Capital, Viking, Deep Track, etc.) piled in for a reason — they see real potential in this dual-agonist for liver and metabolic diseases. Classic early-stage biotech setup: high risk, but the capital injection removes a major worry and sets up the next leg higher if the data delivers.”
Short, straightforward, and realistic no hype, just the setup.
4k on May 15 2.5 C